Grail inc GRAL.US Overview Analysis
GRAL AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
GRAL Current Performance
7.93%
Grail inc
0.23%
Avg of Sector
0.43%
S&P500
Top 10 High Relevance to GRAL
- DOMH Dominari holdings incValue 2Trend 4Swing Trading 3Whale Interest -Dividend 1See more
GRAL Profile
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.